AUTHOR=Taprogge Jan , Abreu Carla , Vávrová Lenka , Carnegie-Peake Lily , Rushforth Dominic , Gape Paul , Gear Jonathan , Murray Iain , Wong Kee H. , Newbold Kate , Yusuf Siraj , Flux Glenn TITLE=Initial results of the INSPIRE clinical trial—investigating radiation dosimetry for differentiated thyroid cancer patients JOURNAL=Frontiers in Nuclear Medicine VOLUME=3 YEAR=2023 URL=https://www.frontiersin.org/journals/nuclear-medicine/articles/10.3389/fnume.2023.964478 DOI=10.3389/fnume.2023.964478 ISSN=2673-8880 ABSTRACT=Introduction

The optimal strategy for differentiated thyroid cancer (DTC) patients treated with radioiodine (RAI) following thyroidectomy remains controversial. Multi-centre clinical studies are essential to identify strategies to improve patient outcomes while minimising treatment-induced toxicity.

Materials and Methods

The INSPIRE clinical trial (ClinicalTrials.gov Identifier: NCT04391244) aims to investigate patient-specific dosimetry for DTC patients and to determine the range of absorbed doses delivered to target and non-target tissues and their relationship with treatment outcome and toxicity.

Results

We report here initial results of the first 30 patients enrolled onto the INSPIRE trial. A large range of absorbed doses are observed for both thyroid remnants and salivary glands, with median values of 4.8 Gy (Range 0.2 – 242 Gy) and 0.3 Gy (Range 0.1 to 1.7 Gy), respectively.

Discussion

The preliminary study results are encouraging and could help to improve our understanding of absorbed doses to thyroid remnants and normal organs following RAI therapy. Such knowledge could potentially enable patient-specific treatment planning with improved clinical outcomes and quality-of-life of patients.